新一代多模式抗抑郁药：聚焦于治疗重度抑郁症的伏硫西汀
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.
作者信息
Katona Cornelius L, Katona Cara P
机构信息
Division of Psychiatry, University College London, London, UK.
North Central London Psychiatry Training Programme, London, UK.
出版信息
Neuropsychiatr Dis Treat. 2014 Feb 19;10:349-54. doi: 10.2147/NDT.S39544. eCollection 2014.
Abstract
Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators. There may be a clinically meaningful advantage in terms of tolerability.
摘要
伏硫西汀是一种新型抗抑郁药，对多种5-羟色胺（5-HT）受体和5-羟色胺转运体均有作用。本文综述了关于其作用机制、耐受性及治疗重度抑郁症疗效的临床前和临床证据。临床研究表明，伏硫西汀对治疗重度抑郁症有效，不过并无证据表明其优于活性对照药。在耐受性方面可能具有临床意义上的优势。
相似文献
1
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.新一代多模式抗抑郁药：聚焦于治疗重度抑郁症的伏硫西汀
Neuropsychiatr Dis Treat. 2014 Feb 19;10:349-54. doi: 10.2147/NDT.S39544. eCollection 2014.
2
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.文拉法辛：新型抗抑郁药的药理学和临床特征综述。
Pharmacol Rep. 2017 Aug;69(4):595-601. doi: 10.1016/j.pharep.2017.01.030. Epub 2017 Feb 1.
3
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.文拉法辛：一种新型抗抑郁药，用于治疗重度抑郁症。
Expert Opin Drug Discov. 2019 Jan;14(1):81-89. doi: 10.1080/17460441.2019.1546691. Epub 2018 Nov 20.
4
[Vortioxetine: a new antidepressant to treat depressive episodes].伏硫西汀：一种治疗抑郁发作的新型抗抑郁药
Encephale. 2016 Feb;42(1):48-58. doi: 10.1016/j.encep.2015.07.007. Epub 2015 Sep 8.
5
Vortioxetine for the treatment of major depression.伏硫西汀用于治疗重度抑郁症。
Drugs Today (Barc). 2013 Dec;49(12):781-90. doi: 10.1358/dot.2013.49.12.2058448.
6
Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.文拉法辛，一种具有多种作用机制的新型抗抑郁药：临床前和临床数据的综述。
Pharmacol Ther. 2015 Jan;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001. Epub 2014 Jul 9.
7
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.伏硫西汀治疗重度抑郁症的概况：主要和次要文献综述
Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015.
8
The efficacy of vortioxetine for the treatment of major depressive disorder.伏硫西汀治疗重度抑郁症的疗效。
Expert Rev Neurother. 2014 Dec;14(12):1349-63. doi: 10.1586/14737175.2014.987131. Epub 2014 Nov 22.
9
Vortioxetine: A new alternative for the treatment of major depressive disorder.伏硫西汀：治疗重度抑郁症的一种新选择。
Rev Psiquiatr Salud Ment (Engl Ed). 2018 Jan-Mar;11(1):48-59. doi: 10.1016/j.rpsm.2017.06.006. Epub 2017 Aug 8.
10
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.抗抑郁药维拉唑酮、左米那普仑和沃替西汀的临床疗效、安全性和耐受性评价。
Expert Opin Pharmacother. 2014 Dec;15(17):2525-42. doi: 10.1517/14656566.2014.960842. Epub 2014 Sep 16.
引用本文的文献
1
AMELIORATIVE EFFECT OF VORTIOXETINE IN EXPERIMENTAL MODEL OF ENDOCRINE PANCREAS DAMAGE RELATED TO CHRONIC UNPREDICTABLE MILD STRESS: AN IMMUNOHISTOCHEMICAL STUDY.伏硫西汀对慢性不可预测轻度应激相关内分泌胰腺损伤实验模型的改善作用：一项免疫组织化学研究。
Acta Endocrinol (Buchar). 2024 Jul-Sep;20(3):269-276. doi: 10.4183/aeb.2024.269. Epub 2025 May 23.
2
Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H Agents: Synthesis and Biological Evaluation.苯丙胺衍生物作为有效的中枢神经系统多靶点 SERT/NET/H 配体：合成与生物学评价。
Molecules. 2024 Nov 6;29(22):5240. doi: 10.3390/molecules29225240.
3
Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism-In Vitro Study.阿戈美拉汀、氯胺酮和沃替西汀对能量细胞代谢的影响——体外研究。
Int J Mol Sci. 2022 Nov 10;23(22):13824. doi: 10.3390/ijms232213824.
4
The molecular pathophysiology of depression and the new therapeutics.抑郁症的分子病理生理学与新疗法
MedComm (2020). 2022 Jul 21;3(3):e156. doi: 10.1002/mco2.156. eCollection 2022 Sep.
5
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases.神经退行性疾病中的内在无序蛋白质及含有内在无序区域的蛋白质
Biophys Rev. 2022 Jun 8;14(3):679-707. doi: 10.1007/s12551-022-00968-0. eCollection 2022 Jun.
6
Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.在经历过与新冠病毒相关创伤的重性抑郁发作患者中，三种抗抑郁药的反应存在差异。
Curr Neuropharmacol. 2022 Nov 15;20(12):2393-2407. doi: 10.2174/1570159X20666220310122849.
7
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.在 PREDDICT 试验中各种抗抑郁药转换为文拉法辛的临床策略。
Int J Neuropsychopharmacol. 2021 Apr 21;24(4):314-321. doi: 10.1093/ijnp/pyaa092.
8
Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus.伏硫西汀对抑郁模型大鼠及海马中脑源性神经营养因子（BDNF）和酪氨酸激酶受体B（Trk B）表达的影响。
Exp Ther Med. 2020 Sep;20(3):2895-2902. doi: 10.3892/etm.2020.9026. Epub 2020 Jul 21.
9
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.一项比较每日一次曲唑酮和文拉法辛缓释剂治疗主要抑郁障碍患者的疗效和安全性的随机、双盲研究。
Int Clin Psychopharmacol. 2020 May;35(3):137-146. doi: 10.1097/YIC.0000000000000304.
10
Paroxetine Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.帕罗西汀与伏硫西汀治疗绝经过渡期抑郁症状的初步研究
Psychopharmacol Bull. 2019 Feb 15;49(1):28-43.
本文引用的文献
1
Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats.孕激素撤退大鼠模型中抗抑郁样作用的 5-羟色胺能受体机制。
Behav Brain Res. 2013 Nov 1;256:520-8. doi: 10.1016/j.bbr.2013.09.002. Epub 2013 Sep 7.
2
Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.涉及文拉法辛（Lu AA21004）的药代动力学药物相互作用，文拉法辛是一种多模式抗抑郁药。
Clin Drug Investig. 2013 Oct;33(10):727-36. doi: 10.1007/s40261-013-0117-6.
3
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.文拉法辛剂量依赖性逆转 5-HT 耗竭诱导的空间工作和物体识别记忆缺陷：5-HT1A 受体激动作用和 5-HT3 受体拮抗作用的潜在作用。
Eur Neuropsychopharmacol. 2014 Jan;24(1):160-71. doi: 10.1016/j.euroneuro.2013.07.001. Epub 2013 Aug 2.
4
Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.通过对小鼠的行为和神经发生结果评估多模式抗抑郁药文拉法辛（Lu AA21004）的抗抑郁和抗焦虑潜力。
Neuropharmacology. 2013 Oct;73:147-59. doi: 10.1016/j.neuropharm.2013.05.014. Epub 2013 May 28.
5
A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition.一项关于新型抗抑郁药文拉法辛（Lu AA21004）对实际驾驶和认知的急性和稳态影响的随机试验。
Clin Pharmacol Ther. 2013 Jun;93(6):493-501. doi: 10.1038/clpt.2013.39. Epub 2013 Feb 20.
6
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.文拉法辛（Lu AA21004），一种新型的多模式抗抑郁药，可增强大鼠的记忆。
Pharmacol Biochem Behav. 2013 Apr;105:41-50. doi: 10.1016/j.pbb.2013.01.019. Epub 2013 Feb 1.
7
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.一项为期 8 周的、针对成人重度抑郁症患者的 2.5mg 和 5mg 伏硫西汀（Lu AA21004）与安慰剂的随机、双盲试验。
Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600. Epub 2013 Jan 17.
8
The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.抗抑郁药文拉法辛诱导的 5-HT 细胞放电的快速恢复涉及 5-HT(3)受体拮抗作用。
Int J Neuropsychopharmacol. 2013 Jun;16(5):1115-27. doi: 10.1017/S1461145712001058. Epub 2012 Oct 22.
9
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.文拉法辛（Lu AA21004）在重度抑郁症的长期开放性标签治疗中的应用。
Curr Med Res Opin. 2012 Oct;28(10):1717-24. doi: 10.1185/03007995.2012.725035. Epub 2012 Sep 17.
10
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.一项为期 6 周、随机、双盲、安慰剂对照的临床试验，评估了 5 毫克伏硫西汀在成人重度抑郁症患者中的疗效和耐受性。
Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21. doi: 10.1017/S1461145712000727. Epub 2012 Sep 11.
Zotero 插件